No, it was discussed on the last CC: Emily Lee: Would

New Post Public Reply Private Reply Replies (0) Message Board
docj Beasley #13888
301
No, it was discussed on the last CC:

Emily Lee: Would you be able to give some color on the diagnostic testing? Are we devising
something there? Do we have any potential partners?
Joe Moscato: Yeah, that is a great question. Dr. Hal Hanes is on, so he can answer that who
runs our subsidiary NuGenerex diagnostics. There are tests right now, Emily,
that the CDC has made up. Those tests have to go to the lab. Obviously, our
technology with our diagnostic company is rapid testing, which can give a
response immediately. This is where it does not go to the lab and you are
waiting 24 to 48 hours to get a result. Hal, maybe you would like to go through
what you have been investigating, as well as what potential we have in creating
a rapid diagnostic handheld kit.
Dr. Hal Hanes: Sure Joe, thanks. That is a great question. If you think about what is happening
right now in China on the ground or in other potential high prevalent areas of
coronavirus infection, people are fearful. They are extremely fearful. You see
condo buildings being shut down in Hong Kong. You see whole cities in China
which have streets that are deserted except for necessities. The coronavirus
infection just basically starts out like a common cold or other infection, which
causes fever and sneezing. It is an upper respiratory virus infection. If you can
diagnose it at an early stage in the disease when people do have these initial
symptoms, you could very likely get them into isolation if they do have the
coronavirus. Make sure they are released if they do not have it. They are not a
danger. They can go home and do what they wish. Right now on incoming
airplanes from China, people are being isolated. You have looked at the news
about cruise ships where there is an outbreak, and the whole cruise ship is stuck
at a dock for two weeks or longer. This is to make sure there is no continual
spread.
Generex Investor Call Feb. 13, 2020
Page 30 of 31
Using Eric’s peptides, we can very likely and almost certainly develop an assay. It
would be an oral fluid assay in which a swab is taken from the throat, nose, or
upper respiratory tract. The virus can be detected directly from that swab on
our proprietary Express 2 platform. This test would take about 10 to 15 minutes
to read. It can be done by minimally trained personnel. They do not have to be
lab techs. They do not have to be nurses or doctors. It can be done in a clinic,
but it can also be used at points of entry by security agents. It is by anybody that
is trained a little bit in running the test. Simply take a swab, put it in the tube,
put the test in the swab of the tube, and it develops. That way people who get
into these high security areas can be screened quickly. By the way, most people
who have these symptoms do not have coronavirus.
There is a lot of overlapping symptomatology like the common cold or flu that
give you the same thing. Right now, if you are in those areas you think you
probably do have the coronavirus. We feel this is going to be a rapid test. It can
be done rapidly. It is cheap to produce once we have the proper peptides. It can
be administered universally practically anywhere. That was a great question
right there. Thanks.
Emily Lee: Is there a timeframe where this can be developed for the test tubes?
Dr. Hal Hanes: Yeah. I can give you an estimate. I certainly do not know. It would require us
taking the peptides that Eric produces and analyze this to make sure they are
proper ones. It is raising antibodies to them in animals. This can be done
relatively quickly. There are lots of animals where it can be done that way. Use
those antibodies as the analytical reagent. In other words, we put them on a
strip. It is like a diabetes strip, except for infectious diseases. We have a lot of
expertise in this. We put them on a strip. We have a control line. We put the
oral fluid after it has been diluted. Let it run up on the strip. The line with the
antibodies to the coronavirus, if there is a coronavirus in that sample, will light
up. The control line will light up. We will be able to say that person does not or
does have coronavirus. I would say probably once the peptides are fully
developed and we can immunize animals with them, there are many companies
that can do this rapidly. We should probably have an assay in three to four
months after those events occur.
Emily Lee: All right. Thank you so much. Are there any interested parties out there? For
example, is the Chinese government aware of this diagnostic test kit that you
guys are?
Dr. Hal Hanes: I think, Joe, you can answer this. I think this is part of the presentation to them
as an aside to the vaccine. Diagnosis goes hand-in-hand together with treatment
or vaccination. You have to have the diagnosis. The vaccination you can use for
everybody. We need to know the diagnosis for people to get treated properly.
Those who have had the virus probably do not need to get diagnosed.
Joe Moscato: Yeah, do not forget too. We are not treatment. We are vaccination.
Generex Investor Call Feb. 13, 2020
Page 31 of 31
Dr. Hal Hanes: Right. Right.
Joe Moscato: Treatment is like a Gilead product. You know? You have corona. You are very,
very sick. You are in a hospital. You have major symptomatic events going on.
Then they give you the Gilead product. Here, we are trying to guard against
severe symptoms at the very least. Guard against severe symptoms. This is all
the way up to full inoculations. That is something that we have discussed with
our Chinese partners. The big interest right now is the vaccine.
Emily Lee: I see. It just seemed like there was such a low supply of test kits. I would think
the test kit should be of great interest too. This is especially recently I read on
the news that some test kits provided to different states or cities are faulty in
the US. I would just think this could be a very huge opportunity.
Joe Moscato: Yeah, we feel the same exact way. I mean, in reality, doing the tests that are
now provided takes time. You have to send them to a lab. The lab has thousands
and thousands of these test kits, I am sure, based upon what is going on out
there. It is going to take time to get those diagnoses. Here, we have a rapid,
ready to go, in-hand test that lets you know five or ten minutes later if that
person is infected. Though we have not made great strides yet in figuring out
how to commercialize that for what is going on right now, the main focus has
been right now the vaccine.
Emily Lee: Okay yeah. Okay great. Thank you so much for your hard work. It sounds
wonderful what you guys are doing. I appreciate your hard work.

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Indico Breach May Expose Thousands to Identity Theft

Updated Category News Views 4

Data Breach Unsettles Indico's Operations Well, this is the kind of headache nobody wants on their spreadsheet—the unpleasant fallout from a significant data breach is rocking Indico Data Solutions. When you hear words like 'unauthorized party' and 'exposed sensitive personal information,' it ought to make investors sit up and pay attention. On May 7, 2026, Indico, the...

Continue Reading
Zepp Health's Q2 2026 Results: Growth Amid Struggles

Updated Category News Views 4

Revenue Growth, Yet the Road Is Rocky Buckle up, investors, because Zepp Health Corporation's (NYSE: ZEPP) latest financials are a bit of a mixed salad—there's some good and some bad tossed in. Reporting a revenue of $63.5 million for the second quarter of 2026, the company managed to eke out a 6.9% increase year-over-year. But before you pop the champagne, let's dig a...

Continue Reading
Acer's New Monitors: ePaper, Triple Displays & More

Updated Category News Views 8

Next-Gen Screens: Breakthrough or Bust? So, Acer’s stepping up its game, unveiling an armory of gadgets designed to cement their spot in the tech arena. On the menu today? ePaper displays and enhanced connectivity gizmos that could either tip the scales or sink like a stone. Keep your eyes peeled, though—these updates aren't just another throwaway press release....

Continue Reading
BOC Group's Challenger Role Eye-Opener in Gartner Quadrant

Updated Category News Views 6

Cracking the Challenger Code: BOC Group's Debut Ever heard of BOC Group? If you haven’t, it’s time to pay attention. This Dublin-based outfit just muscled its way into the Challenger Quadrant of the 2026 Gartner Magic Quadrant for Digital Twin of an Organization Platforms. Not bad for its first trip to the dance. When a company crashes the scene like this, eyebrows...

Continue Reading
Ivonescimab Shows Strong Survival in Key Lung Cancer Trial

Updated Category News Views 0

New Frontiers in Lung Cancer Treatment Well, here's a story that rattles the cage in the oncology world. The name of the game is ivonescimab, Akeso’s latest move as they toss their hat into the already crowded yet pivotal lung cancer treatment ring. This isn't just some side hustle—they've got Phase III data pointin' straight north, figuratively casting a shadow over...

Continue Reading
Volato Group Faces Merger Scrutiny Amid SOAR Deal

Updated Category News Views 2

Unraveling the Volato Merger Drama Boy, the plot thickens with Volato Group, Inc. (SOAR), and it ain’t the first time we’ve seen this kind of shuffle in the market. Now, Volato’s got itself tangled up with Alignment Engine Inc. through a proposed merger. Sounds routine at first; we all know mergers are part of the corporate game. But here's the twist—shareholders...

Continue Reading
Kareem's Lebanese Kitchen: A Culinary Tribute to Maryland

Updated Category News Views 4

Embracing Tradition with a Modern Twist Well, here's to new beginnings wrapped in old flavors, folks. September 1, 2026, marks the arrival of Kareem's Lebanese Kitchen at Rio Lakefront in Gaithersburg, Maryland. It's where the Mediterranean meets the Chesapeake in an unexpected culinary celebration. Chef Rachid Eido's Legacy Third-generation Lebanese Chef Rachid Eido is...

Continue Reading
RealityMine Appoints CPO Amidst Strong Growth Momentum

Updated Category News Views 0

Pushing the Boundaries of Behavioral Data When a company like RealityMine posts a whopping 75% year-over-year revenue bump, you know they're not here to mess around. Enter Soumya Bijjal, a seasoned pro stepping in as their inaugural Chief Product Officer. This isn't just about adding to the C-suite boys' club; it's about locking in on a goldmine of behavioral data that's...

Continue Reading
Kroger's Strategic Shift: Ibbotson's Bold New Charge

Updated Category News Views 0

Kroger Welcomes a Seasoned Retail Veteran Change often arrives with the dawn of new leadership. As Kroger takes a page from the playbook of large-scale retail transformation, they've enlisted Mark Ibbotson. Effective September 14, Ibbotson will step in as Executive Vice President and Chief Store Operations Officer. It's a roll of the dice that could either accelerate...

Continue Reading
Innventure Faces Class Action Over Alleged Deception

Updated Category News Views 3

Unpacking the Innventure Debacle Innventure, Inc. (NASDAQ:INV) seems to have landed itself in hot water, and not the relaxing kind. The revelation that its grand AI data center project in Ontario might never have existed has stirred up quite a storm among shareholders. This isn't just some run-of-the-mill oversight. We're talking about allegations of concocted stories...

Continue Reading

Top 5 Most Recently Viewed Articles

ABN AMRO Advances Share Buyback Program with Key Updates

Updated Category News Views 207

ABN AMRO's Share Buyback Program Progress Overview ABN AMRO has recently reported significant advancements regarding its EUR 250 million share buyback program that was announced earlier in the month. This initiative aims to bolster shareholders' value and demonstrate the bank's commitment to enhancing its financial position. Transaction Details and Financial Insights...

Continue Reading
Exploring Recent Options Activity in Robinhood Markets Stock

Updated Category News Views 80

What Recent Options Trades Say About Robinhood Markets Investors are leaning bearish on Robinhood Markets, and the options tape shows it. Recent flow highlights how larger traders are setting up, offering a clear read on sentiment without guessing at motives. Breaking Down the Recent Trades In our review of options activity for Robinhood Markets (NASDAQ: HOOD), we counted...

Continue Reading
Neuronetics Enhances Registration Rights for Shareholders

Updated Category News Views 108

Neuronetics Amends Registration Rights Agreement Neuronetics, Inc. (NASDAQ: STIM), a pioneering medical technology firm, has recently made significant changes to its Registration Rights Agreement with Madryn Asset Management LP. This amendment extends the period for Madryn to demand the registration of their acquired shares, increasing the Demand Registration Period from...

Continue Reading
Macy's Sales Performance and Strategic Outlook for the Holidays

Updated Category News Views 168

Insights into Macy's Recent Performance Macy’s Inc (NYSE: M) has recently revealed its sales dynamics, indicating that even during a period of stronger financial results, its stock took a slight dip. Despite a notable improvement in sales, profit, and comparable growth metrics, the market response has been tempered, reflecting complex customer behaviors ahead of the...

Continue Reading
Steward Partners Celebrates Seven Teams in Forbes Rankings

Updated Category News Views 97

Celebrating Steward Partners' Remarkable Forbes Recognition Top honors reflect exceptional service, teamwork, and commitment to excellence Steward Partners, a thriving independent financial services firm known for its employee-owned model, recently celebrated a significant achievement. The firm proudly announced that seven of its partners have been recognized in the...

Continue Reading